The drug is an oncolytic virus (basically a modified herpes virus) with a benign side effect profile (some patients got temperature as if having a cold but not more than that). The virus is injected into tumours. Interestingly not only the tumour itself shrinks or even disappears but also (non-injected) tumours in other parts of the body show response (or full remission). According to the companies homepage the response rate in phII trials are 28% (8% partial response; 20% complete response). 52% survival after 2 years. This is quite remarkable as these patients were in stageIIIc and stageIV melanoma and some had metastases all over their body.
Will be interesting to see how good the drug works in phIII. But if it works this could be marketed very soon and clearly has some blockbuster potential.
News 
Market Data 
Discover 
AI
